Thursday 28 January 2021 ,
Thursday 28 January 2021 ,
Latest News
  • PM details vaccine roll-out plan in JS
  • CCC polls: 2 killed in election-related violence with voting underway
  • Covid-19 vaccination drive begins today
  • India farmer leaders condemn violence but won't call off protests
  • Bangladesh a golden investment destination for potential Chinese investors: Li Jiming
  • Special Team arrives in Sylhet to test Corona-affected UK returnees
  • PM places six proposals before world to stop random use of antibiotics
30 November, 2020 06:09:37 PM / LAST MODIFIED: 1 December, 2020 09:08:23 AM
Print

Covid vaccine: Moderna files for approval in US

BBC, London
Covid vaccine: Moderna files for approval in US
Image Credit: Getty

Moderna is filing for US regulatory approval of its coronavirus vaccine so that it can be recommended for widespread use.

The Food and Drug Administration will look at trial data for the mRNA vaccine and decide if it is safe and effective enough for Emergency Use Authorization.

Clinical studies show the jab is more than 94% effective at protecting people from becoming ill with Covid-19.

Pfizer, which has a similar jab, has already filed for the same US approval.

UK regulators are also reviewing data on the Pfizer vaccine, as well as another type of Covid vaccine from AstraZenca and Oxford University for emergency approval.

Moderna says it is plans to file for UK approval soon, now that it has trial data from 30,000 volunteers - including high risk groups like the elderly - that suggests it works.

These three front-runner vaccines have different pros and cons.

The AstraZeneca jab is cheaper - around £3 ($4) for a dose, compared to around £15 ($20) for the Pfizer vaccine and £25 ($33) for Moderna's.

And it is potentially easier to distribute because it does not need to be stored under ultra-low temperatures.

But its efficacy in trials - between 62% and 90% - is a bit lower than the Pfizer and Moderna vaccines.

The UK has already pre-ordered doses of all three vaccines:

7m of the Moderna jab
40m of the Pfizer/BioNTech one
100m of the AstraZeneca Oxford vaccine

Dr Alexander Edwards, associate professor in biomedical technology at the University of Reading, said: "This is great news indeed - the more trial data that we have, the greater confidence we have that vaccines can be used to blunt the human cost of Covid-19.

"As the numbers of cases reported grows, confidence grows that this amazing protection will be maintained in a product that can be rolled out to protect the public."

 

SI

 

Comments

Video

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting